Concord Biotech bonus issue sparks rally! Pharma stock jumps 6% on maiden share reward - Top things to know
Concord Biotech shares surged nearly 6% after announcing a bonus issue. The board will meet on September 23, 2026, to discuss issuing bonus shares to existing shareholders.
Concord Biotech bonus issue: Shares of Concord Biotech Limited rallied nearly 6% during Monday’s trading session after the pharmaceutical major announced a crucial bonus issue update. The company’s board of directors are scheduled to meet and consider the corporate action this week.
This will be the first instance that the Gujarat-headquartered pharmaceutical company will issue bonus shares to its stock holders. Here are all the details of the Concord Biotech bonus issue.
The company’s board of directors is set to meet on Wednesday, September 23, 2026. The board will inter-alia “to consider the proposal for declaration of bonus equity shares to the existing equity shareholders of the Company in accordance with the applicable provisions, subject to approval of the shareholders of the Company.”
The company will announce record date details related to bonus issue soon. Investors interested in the corporate action must own the stock before the record date to become eligible for the payout.
The company stock was trading 5.23% higher at ₹ 1572.05 per share on BSE with a market capitalisation of ₹ 16,446.19 crore at 3:29 pm on Monday. The stock had touched an intraday high of ₹ 1,592.05 per share and an intraday low of ₹ 1,512.70 per share.
The stock touched its 52-week high of ₹ 1,702.10 per share on September 19, 2025. The stock dipped to its 52-week low of ₹ 987.05 per share on April 2, 2026. It has a return on equity (ROE) of 17.72%. Its share price value has surged around 43.9% in six months, 19.4% in three months, and 17.58% in 2026 so far. The company stock has risen 7.06% in one year, and around 39.46% in two years.
The firm has reported a net profit of ₹ 61.19 crore in the June quarter of financial year 2026-27, against a net profit of ₹ 90.02 crore in the March quarter of FY26. Its net revenue declined to ₹ 260.52 crore in Q1FY27 against ₹ 325.89 crore in the March quarter of FY26. The company’s earnings per share (EPS) stood at ₹ 5.85 in Q1FY27 against ₹ 8.60 in Q4FY26.
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.
